{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009849","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.532012+00:00","generated_at":"2026-05-21T15:13:13.206747+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack receives ethics approval for 1-year CBGM clinical study in diabetes patients","bullets":["Ethical approval from St. Vincent's Hospital Melbourne HREC for long-term CBGM study in type 1/2 diabetes.","Study plans up to 30 participants; initial 1-year evaluation, possible extension to 3 years.","First patient implants expected by July 2025; Principal Investigators Prof. David O'Neal and Assoc. Prof. Neale Cohen.","CBGM is implantable, measures blood glucose directly (vs interstitial fluid), no wearable component."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009849","json":"https://secwatch.observer/filing/0001641172-25-009849.json","markdown":"https://secwatch.observer/filing/0001641172-25-009849.md","text":"https://secwatch.observer/filing/0001641172-25-009849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225009849/0001641172-25-009849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225009849/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:13:13.206747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}